Navigation Links
Gen-Probe to Webcast Four Upcoming Investor Presentations

SAN DIEGO, Sept. 3 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) announced today that the Company will present at the following investor conferences:

  • Baird's 2009 Health Care Conference in New York at 2:45 p.m. Eastern Time (ET) on September 9.
  • Thomas Weisel Partners' Healthcare Conference 2009 in Boston at 9:45 a.m. ET on September 10.
  • The 2009 Morgan Stanley Global Healthcare Unplugged Conference in New York at 8:35 a.m. ET on September 14.
  • Think Equity's Sixth Annual Growth Conference in San Francisco at 1 p.m. ET on September 15.

These presentations are scheduled to be webcast live and may be accessed through a link on the investors section of Gen-Probe's website at The webcasts will be available for 30 days following the events.

About Gen-Probe

Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs) that are used primarily to diagnose human diseases and screen donated human blood. Gen-Probe has more than 25 years of NAT expertise, and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening. Gen-Probe is headquartered in San Diego and employs approximately 1,200 people. For more information, go to

Caution Regarding Forward-Looking Statements

Any statements in this press release about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. For information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we have filed with the SEC, including the Form 10-Q for the period ended June 30, 2009, and all subsequent periodic filings made with the SEC. We assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.


    Paula Izidoro
    Investor Relations

SOURCE Gen-Probe Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Gen-Probe to Webcast Two Upcoming Investor Presentations
2. Gen-Probe Completes Acquisition of Tepnel Life Sciences
3. Gen-Probe to Webcast Two Upcoming Investor Presentations
4. Gen-Probe Borrows $170 Million Under New Line of Credit
5. Eric Lai Joins Gen-Probe as Senior Vice President, Research and Development
6. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2008 Earnings Conference Call
7. Promising Clinical Data on Gen-Probes APTIMA(R) HPV Test Presented at Major European Medical Meeting
8. Gen-Probe to Webcast Presentation at the Lazard Capital Markets 5th Annual Healthcare Conference
9. Gen-Probe to Webcast Presentation at the UBS Global Life Sciences Conference
10. Gen-Probe to Webcast Presentation at the Bank of America 38th Annual Investment Conference
11. Gen-Probe to Webcast Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
(Date:6/27/2016)... , ... June 27, 2016 , ... ... bring innovative medical technologies, services and solutions to the healthcare market. The company's ... of various distribution, manufacturing, sales and marketing strategies that are necessary to help ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... 23, 2016  The Prostate Cancer Foundation (PCF) is pleased to ... faster cures for prostate cancer. Members of the Class of 2016 were selected ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:6/7/2016)... 2016  Syngrafii Inc. and San Antonio Credit ... includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution ... will result in greater convenience for SACU members ... maintaining existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing ...  3D medical LCD display is the latest premium product recently added to the range ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):